KFDA vs FDA vs EU: Cosmetic Safety Standards for K-Beauty Brands Selling Globally in 2026
Korea (MFDS) uses a post-market reporting system with special "functional cosmetics" review for efficacy claims. The US (FDA/MoCRA) now requires facility registration, product listing, and adverse event reporting, with biennial renewal due by July 2026. The EU runs the strictest pre-market system: every product needs a Responsible Person, a safety report (CPSR), and CPNP notification before the first unit ships. A K-beauty brand selling in all three markets needs three distinct compliance tracks running simultaneously.
Your Korean ODM just confirmed the final formula. Production starts in six weeks. Then your US regulatory consultant flags that your facility registration renewal is overdue, your EU distributor asks for the updated Product Information File, and you realize your sunscreen's SPF claim triggers a completely different approval category back in Korea.
This is the reality for any K-beauty brand selling across Korea, the US, and Europe in 2026. Three regulatory systems, three sets of deadlines, three definitions of what counts as a "cosmetic." Below is a practical breakdown of each system and what you actually need to do before shipping product.
- Korea's MFDS is rolling out a mandatory safety assessment system starting with pilot programs in 2026, full enforcement by 2031
- Facility registrations renew every two years from each facility’s initial registration date. There is no single universal renewal deadline
- The EU banned retinol above 0.05% in body lotions (Nov 2025) and requires pre-market CPNP notification with no grace period
- Only the EU requires appointing a local Responsible Person; US and Korea allow foreign-based responsible entities
- A single product claiming "anti-wrinkle + SPF" triggers functional cosmetics review in Korea, while the same product is just a cosmetic in the US and EU
By Liz Song, K-beauty sourcing consultant
Korea's MFDS Framework: What Changed in 2026
Korea's MFDS (formerly called KFDA) governs cosmetics under the Cosmetics Act, which separates products into "general cosmetics" and "functional cosmetics." General cosmetics only require a post-market report to MFDS. Functional cosmetics, which include products claiming whitening, wrinkle improvement, UV protection, hair coloring, or anti-hair loss effects, require pre-market review with efficacy data before they can be sold.
The biggest 2026 development: MFDS announced a three-pillar regulatory overhaul on April 1, 2026. The first pillar is a mandatory cosmetic safety assessment system. MFDS launched a support program offering one-on-one consulting for 1,500 small and mid-sized cosmetic companies to help them prepare. Pilot programs run through 2026 and 2027, phased implementation begins in 2028 by company size, and full enforcement is expected around 2031.
The second pillar is an e-labeling framework that will eventually allow digital labels. The third is inter-ministerial coordination between MFDS and other government agencies on cosmetics oversight.
For ingredient management, MFDS uses a positive-list system for preservatives, UV filters, and color additives. If you want to use an ingredient not on the approved list, you need separate MFDS approval. In 2026, MFDS also proposed reclassifying seven restricted hair dye ingredients as fully prohibited.
How Does MoCRA Change US Market Entry?
MoCRA, the US federal law requiring cosmetic facility registration and product listing (FDA overview), transformed the US from the most lenient major market to a moderately regulated one. Every facility manufacturing or processing cosmetics for US distribution must register with the FDA and list every product. More than 14,000 facilities have registered so far.
The critical 2026 deadline: biennial facility registration renewal. If your facility first registered in early 2024, your renewal was due in early 2026. Facility registrations renew every two years from the facility’s initial registration date. There is no single universal renewal deadline. The FDA updated its Cosmetics Direct portal in February 2026 with new "Registration Status" and "Renewal Date" fields to help track compliance.
Small businesses with under $1 million in average annual US cosmetic sales are exempt from facility registration, product listing, and (once finalized) GMP requirements. But this exemption disappears if your product contacts the eye's mucous membrane, is injectable, or is intended for internal use. And even exempt businesses must still report serious adverse events to the FDA within 15 business days and keep records for six years.
The FDA also launched its Adverse Event Monitoring System (AEMS) in March 2026, routing cosmetic adverse event reports through the same infrastructure as drug and device reports. Every product label must now include domestic contact information (address, phone, or website) for adverse event reporting.
The EU's Pre-Market System Is the Strictest of All Three
The EU's Cosmetics Regulation (EC 1223/2009) requires more compliance work upfront than either Korea or the US. Before placing any cosmetic product on the EU market, you must: appoint an EU-based Responsible Person (RP), prepare a Product Information File (PIF) including a Cosmetic Product Safety Report (CPSR), and notify the product through the CPNP portal. There is no grace period. Products found on the market without CPNP notification face immediate withdrawal orders.
Korean ODM manufacturers cannot serve as the EU Responsible Person because they are outside the EU. You either designate your EU-based importer as the RP or hire a third-party regulatory consultancy. Annual costs start around €800 per year for up to five products, plus additional fees if you need CPSR preparation or notification support.
Recent ingredient restrictions matter for K-beauty formulations. Since November 1, 2025, retinol is capped at 0.05% in body lotions and 0.3% in other leave-on and rinse-off products, with mandatory label warnings about daily Vitamin A intake. Products with triclosan and triclocarban that don't meet new restrictions also lost EU market access as of October 31, 2025. Non-compliant products already on shelves have until May 1, 2027 to sell through.
Side-by-Side: Registration, Testing, and Timelines
| Requirement | Korea (MFDS) | US (FDA/MoCRA) | EU (EC 1223/2009) |
|---|---|---|---|
| Pre-market approval | Only functional cosmetics | No (registration + listing) | CPNP notification required |
| Responsible Person | Cosmetic Responsible Seller (can be foreign) | US-based RP required | EU-based RP mandatory |
| Safety assessment | Mandatory from 2028 (pilot 2026) | Safety substantiation required | CPSR mandatory before sale |
| Facility registration | Required for manufacturers | Biennial renewal (July 2026) | GMP (ISO 22716) required |
| Adverse event reporting | Required for serious events | 15 business days (serious) | Serious Undesirable Effects reported |
| Small business exemption | Safety assessment phased by size | Under $1M sales exempt | No exemptions |
| Recent ingredient changes | 7 hair dye ingredients → prohibited | State-level bans emerging | Retinol caps + triclosan ban |
Common Compliance Mistakes K-Beauty Brands Make
The most expensive mistake is assuming Korean compliance transfers to other markets. It does not. A product fully approved as a functional cosmetic in Korea still needs separate FDA registration and EU CPNP notification. Here are the mistakes I see most often:
Treating "cosmetic" as a universal category. A product with SPF 50 is a functional cosmetic in Korea, a cosmetic in the EU, and an OTC drug in the US (regulated by the FDA's drug division, not its cosmetics division). A single SKU can fall under three completely different regulatory categories depending on the market.
Missing the MoCRA renewal window. Biennial renewal is anchored to your initial registration date, not a fixed calendar deadline. If you registered February 20, 2024, your renewal was due February 20, 2026. Check the Cosmetics Direct portal for your specific date.
Skipping the EU Responsible Person. Korean brands sometimes try to self-designate as their own RP, but the RP must be established within the EU. Using your Korean ODM's address on the label does not satisfy this requirement and will trigger a market withdrawal.
Ignoring EU ingredient caps in K-beauty formulations. Retinol-heavy serums and ampoules are popular in K-beauty. If your formulation exceeds 0.3% retinol (or 0.05% for body lotions), it cannot legally be sold in the EU as of November 2025. Reformulation takes time, so plan ahead. For more on how K-beauty formulation costs break down, see our specialty manufacturing cost guide.
Your Three-Market Checklist Before First Shipment
Running compliance for Korea, the US, and the EU simultaneously requires tracking different timelines, different documentation, and different contacts. Here is what needs to be ready before your first shipment to each market:
For Korea: Confirm whether your product qualifies as general or functional. If functional, submit for MFDS review with efficacy data before production. Register your manufacturing facility. Start preparing for the mandatory safety assessment system (pilot phase begins now, enforcement from 2028).
For the US: Register your facility on FDA's Cosmetics Direct. List every product (Form FDA 5067). Designate a US-based Responsible Person. Ensure your label includes domestic contact info for adverse event reporting. Set a calendar reminder for biennial renewal. If your ODM is based in Korea, check if they also need US facility registration, as required for manufacturers of US-distributed cosmetics. For context on finding the right manufacturer, see our guide to finding a Korean cosmetics manufacturer.
For the EU: Appoint an EU-based Responsible Person. Commission a Cosmetic Product Safety Report (CPSR) for each product. Notify through CPNP before the first sale. Ensure GMP compliance (ISO 22716). Cross-check every ingredient against the latest Annex II (prohibited), Annex III (restricted), and Annex IV-VI (positive lists). Pay special attention to retinol and triclosan formulations.
"A founder came to us last month with a retinol serum line that was selling well in Korea. She wanted to expand into Europe and the US simultaneously. By the end of a single call, we had mapped out which SKUs needed reformulation for EU retinol caps, which ones needed MoCRA registration, and the exact timeline to get everything compliant before her Q4 launch window."
If you're navigating multi-market compliance, I do a free 15-minute gut-check call. No pitch, just answers.
FAQ
Can I use the same product label for all three markets?
No. Each market has different labeling requirements. Korea requires Korean-language labels with MFDS-specified ingredient names. The US requires English labels with FDA-compliant ingredient nomenclature and the Responsible Person's contact details. The EU requires labeling in the official language(s) of the member state where the product is sold, plus the RP's name and address. Most brands create market-specific sleeve labels or stickers.
Do I need animal testing data for any of these markets?
The EU has a complete ban on animal testing for cosmetics, both for finished products and ingredients. Korea phased out mandatory animal testing for general cosmetics but still requires it for some functional cosmetic categories unless alternative test data is accepted. The US does not require animal testing but does not prohibit it at the federal level (several states have their own bans).
What happens if I miss the MoCRA facility renewal deadline?
FDA has not yet announced specific enforcement actions for missed renewals, but your registration status will show as lapsed in the Cosmetics Direct system. This could affect import clearance and signal non-compliance during inspections. The registration renewal process itself is free and can be completed online through FDA's Cosmetics Direct portal.
Is CBD or hemp-derived ingredient allowed in cosmetics across these markets?
This is a rapidly evolving area. Korea currently prohibits CBD in cosmetics. The US permits hemp-derived ingredients (with THC below 0.3%) in cosmetics but the FDA has not approved CBD as a cosmetic ingredient and continues to issue warning letters. The EU allows some hemp seed derivatives but restricts CBD itself, with individual member states applying varying interpretations.
- U.S. Food and Drug Administration. "Modernization of Cosmetics Regulation Act of 2022 (MoCRA)." fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022
- U.S. FDA. "Cosmetics Direct: Facility Registration and Product Listing." fda.gov/cosmetics/registration-listing-cosmetic-product-facilities-and-products/cosmetics-direct
- U.S. FDA. "FDA Adverse Event Monitoring System (AEMS)." fda.gov/cosmetics/cosmetics-compliance-enforcement/adverse-event-reporting-cosmetics
- Ministry of Food and Drug Safety (MFDS), Republic of Korea. "Cosmetics Safety Management Reform Announcement." April 1, 2026. mfds.go.kr
- MFDS. "Cosmetics Act (화장품법): Functional Cosmetics Classification and Review Requirements." law.go.kr
- European Commission. "Regulation (EC) No 1223/2009 of the European Parliament and of the Council on Cosmetic Products." eur-lex.europa.eu
- European Commission. "Commission Regulation (EU) 2024/996: Retinol, Retinyl Acetate, and Retinyl Palmitate Concentration Limits." November 2025 enforcement. eur-lex.europa.eu
- European Commission. "Cosmetic Products Notification Portal (CPNP)." ec.europa.eu/growth/sectors/cosmetics/cpnp_en
Liz Song is a K-beauty sourcing consultant and founder of ALTA MEET, helping indie beauty founders navigate Korean ODM partnerships, regulatory compliance, and global market entry. Based in New York, she bridges the gap between Korean manufacturers and Western brands launching K-beauty-inspired products.
